A review of one research paper.

Our review questions

Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial

Study review

In preparation

Not independently approved.

Paper published: Not recorded

Study at a glance

DOI
10.1111/dom.14765

Key limitation: A full assessment of this paper is not yet available. Its presence in the library does not establish benefit or safety.

0

Review in preparation

This paper has a dedicated review record, but its full study appraisal is not yet available. It has not been counted as a completed review.

0 of 15 questions answered; 0 partly resolved; 15 awaiting assessment.

The original paper and references remain available above.